Search

Halozyme Therapeutics Inc

Closed

SectorHealthcare

77.87 0.34

Overview

Share price change

24h

Current

Min

77.11

Max

79.47

Key metrics

By Trading Economics

Income

292M

150M

Sales

-75M

377M

P/E

Sector Avg

26.737

60.149

EPS

1.221

Profit margin

39.832

Employees

423

EBITDA

-62M

220M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+4.46% upside

Dividends

By Acuity

Next Earnings

4 Aug 2026

Market Stats

By TradingEconomics

Market Cap

1.4B

9B

Previous open

77.53

Previous close

77.87

News Sentiment

By Acuity

50%

50%

155 / 340 Healthcare

Halozyme Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

17 Jul 2026, 23:56 UTC

News
Social Media

Micron Technology shares are lower in after-market trading amid a decline in India's smartphone shipments and ongoing memory cost pressures affecting margins.

17 Jul 2026, 23:36 UTC

News

GameStop increased its stake in eBay to nearly 10%, acquiring 3.5 million shares for about $381 million. eBay shares are gaining in after-market trading.

17 Jul 2026, 23:36 UTC

Macro News
News
ETF Constituents

Vanguard Information Technology ETF rises slightly in after-market trading, supported by gains in Microsoft, Analog Devices, Adobe, Qualcomm, and Snowflake.

17 Jul 2026, 23:21 UTC

Social Media
News
Correlated Moves

Meta Platforms Inc. shares declined in after-market trading amid concerns over $125 billion to $145 billion in projected AI spending and slower development timelines.

17 Jul 2026, 23:16 UTC

News

United Airlines reported record Q2 revenue of $17.7 billion, a 16% increase. Shares were little changed during after-market hours following the announcement.

17 Jul 2026, 23:16 UTC

News
Social Media

PayPal Holdings Inc shares are lower in after-market trading amid reports of a potential bid, though analysts remain cautious about growth prospects.

17 Jul 2026, 23:16 UTC

News
ETF Constituents
Macro News
Correlated Moves

GDX trades higher in after-market hours, supported by positive analysis and strong performance expectations amid rising geopolitical tensions and crude oil prices.

17 Jul 2026, 23:06 UTC

News

Baidu Inc. partners with Apple to enhance its AI capabilities and pursues a dual-primary listing in Hong Kong, shares higher in after-market trading.

17 Jul 2026, 23:06 UTC

ETF Constituents
News

Vanguard Growth ETF trades lower in after-market hours, continuing a downward trend. Top holdings META, AMAT, and LLY negatively impacted performance.

17 Jul 2026, 20:07 UTC

News
Social Media

European Union approval is anticipated for the $55 billion acquisition of Electronic Arts by a group of investors, including Saudi Arabia's Public Investment Fund.

17 Jul 2026, 20:07 UTC

News
Social Media

Tesla Inc shares are lower as investors await the earnings report on July 22. Concerns over Semi truck rollout and autonomous driving goals weigh on sentiment.

17 Jul 2026, 20:07 UTC

Macro Event
Social Media
Correlated Moves
News

Broadcom shares declined to around $371.69 today, amid increased bearish sentiment and concerns over potential breakdowns below key support levels.

17 Jul 2026, 20:07 UTC

News

Ethereum is trading lower as geopolitical tensions and rising oil prices heighten inflation concerns. Ongoing worries about tech valuations also impact its performance.

17 Jul 2026, 20:07 UTC

News

Bitcoin is rising during Friday's session amid geopolitical tensions and rising oil prices, though it has pulled back from earlier session highs.

17 Jul 2026, 20:07 UTC

News
Macro Event

Geopolitical tensions and rising oil prices support Bitcoin's gains during Friday's session, despite earlier pullbacks and regulatory scrutiny from former President Trump.

17 Jul 2026, 20:03 UTC

News

J B Hunt shares are lower as freight shipments decline and inflationary pressures persist. The Cass Freight Index reported a 4.1% year-over-year drop in June.

17 Jul 2026, 20:03 UTC

News
Social Media
Correlated Moves

Western Digital Corp shares are higher, supported by projected revenue growth of 43.7% and improved operating margins, despite earlier volatility and a pullback from session highs.

17 Jul 2026, 20:03 UTC

News
Macro Event

Ulta Beauty is gaining as Evercore highlights its innovation amid positive consumer sentiment data, despite an earlier pullback from session highs.

17 Jul 2026, 20:03 UTC

Correlated Moves
News
Social Media

Alphabet Inc. shares are declining amid reports of delays in the Gemini project rollout, overshadowing BMO's price target increase to $455.

17 Jul 2026, 20:03 UTC

News
Correlated Moves
Social Media

Alphabet Inc shares are lower amid a securities fraud investigation and delays in its AI model rollout. BMO raised its price target to $455.

17 Jul 2026, 20:02 UTC

News

Wynn Resorts Ltd is lower amid broader market declines and a negative outlook from StockStory, citing financial challenges and modest sales growth.

17 Jul 2026, 20:01 UTC

News

NetApp Inc. shares are higher as StockStory highlights a $177.25 price target and strong growth in billings and earnings per share.

17 Jul 2026, 19:56 UTC

News

Gilead Sciences shares are lower as the company missed full-year EPS estimates despite reporting $6.96 billion in revenue, reflecting heightened market volatility.

17 Jul 2026, 19:56 UTC

News
Social Media

Apple Inc. is in early settlement discussions regarding an antitrust lawsuit. The company regained its status as the world's most valuable, surpassing Nvidia.

17 Jul 2026, 19:52 UTC

News
Social Media
Correlated Moves

NVIDIA shares are declining amid a broader semiconductor sell-off and competitive concerns from Moonshot AI's new model. Apple has surpassed NVIDIA in market value.

17 Jul 2026, 19:52 UTC

News
Correlated Moves

NXP Semiconductors NV is trading lower amid a broader market decline and rising pressures in the semiconductor industry, impacting its valuation narrative.

17 Jul 2026, 19:52 UTC

News
Social Media
Correlated Moves

AMD declines today amid broader market losses, pulling back from session high.

17 Jul 2026, 19:46 UTC

Social Media
News
Macro Event

Shares of American Airlines are lower today, trading around $15.03 amid increased bearish sentiment reflected in a rising put/call ratio of 1.61.

17 Jul 2026, 19:46 UTC

Social Media
Correlated Moves
News

CSX shares are lower as Daniel Loeb exits his 500,000-share position, following significant cuts in other railroad investments amid regulatory scrutiny.

17 Jul 2026, 19:46 UTC

News
Macro Event

Autodesk announces a collaboration with Amazon Web Services and raises revenue guidance to $8.5 billion, as shares gain during Friday's session.

Peer Comparison

Price change

Halozyme Therapeutics Inc Forecast

Price Target

By TipRanks

4.46% upside

12 Months Forecast

Average 81 USD  4.46%

High 96 USD

Low 57 USD

Based on 6 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

3

Buy

2

Hold

1

Sell

Sentiment

By Acuity

155 / 340 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat